Key Developments: Virbac SA (VIRB.PA)

VIRB.PA on Paris Stock Exchange

200.75EUR
28 Aug 2015
Change (% chg)

€-1.25 (-0.62%)
Prev Close
€202.00
Open
€202.00
Day's High
€203.30
Day's Low
€199.30
Volume
3,578
Avg. Vol
7,451
52-wk High
€257.95
52-wk Low
€146.55

Search Stocks

Latest Key Developments (Source: Significant Developments)

Virbac gives various FY 2015 guidance with no estimates
Tuesday, 23 Jun 2015 12:00pm EDT 

Virbac SA:Group's perspectives for 2015 impacted by the industrial situation in the United States.U.S. affiliate will ultimately suffer in 2015 from a significant drop in revenue generated by its historical range.Current operating result of this affiliate in 2015 is now expected to decrease despite integration of Sentinel.This situation might result in a decrease of group's current operating profit in 2015.For first half-year, current operating profit is already expected to show a significant decrease as compared to same period of 2014.  Full Article

Virbac proposes stable FY 2014 dividend
Friday, 24 Apr 2015 11:12am EDT 

Virbac SA:Proposes stable FY 2014 dividend of 1.90 euros per share.  Full Article

Virbac closes Sentinel brands family acquisition Eli Lilly
Monday, 5 Jan 2015 02:28am EST 

Virbac SA:Announces closing of Sentinel brands family acquisition in United States from Eli Lilly.Acquisition closed on Jan. 2.  Full Article

Nexvet Biopharma Pty Ltd announces collaboration and distribution agreement with Virbac SA
Wednesday, 3 Dec 2014 05:30am EST 

Nexvet Biopharma Pty Ltd:Says signing of a ten year collaboration and distribution agreement with Virbac SA.Virbac will distribute NV-01, Nexvet's product, in territories outside the U.S. and Canada. NV-01 is an anti-nerve growth factor monoclonal antibody (mAb) for the control of pain associated with osteoarthritis in dogs.  Full Article

Virbac to acquire United States veterinary assets from Eli Lilly
Monday, 27 Oct 2014 02:33am EDT 

Virbac SA:Agrees to acquire veterinary assets from Eli Lilly in United States.Says deal is for veterinary products marketed by Novartis Animal Health.Says assets to be acquired are related to two parasiticides for dogs, namely Sentinel Flavor Tabs and Sentinel Spectrum.Says deal is subject to approval by Federal Trade Commission and conditioned on closing of acquisition of Novartis Animal Health by Eli Lilly.  Full Article

Virbac to propose terms of share repurchase program
Thursday, 22 May 2014 11:21am EDT 

Virbac SA:To propose terms of share repurchase program to annual general meeting on June 17.Taking into account shares already held by company, program would authorize repurchase of up to 816,298 shares, or 9.7 pct of share capital.Maximum price per share 300 euros.Total maximum that could be spent 244,889,400 euros.Authorization valid for 18 months.  Full Article

Virbac proposes FY 2013 dividend
Wednesday, 19 Mar 2014 12:45pm EDT 

Virbac SA:Proposes unchanged FY 2013 dividend of 1.90 euro per share, paybale on June 25.  Full Article

BRIEF-Virbac H1 sales grow by 18.1 pct to 432.5 million euros

* Consolidated revenue in Q2 amounted to 221.1 million euros ($241.11 million), a 19.0 pct growth compared to same period of last year

Search Stocks